We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
Cap. Flow
+$122M
Cap. Flow %
183.83%
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72

Top Buys

1
INCY icon
Incyte
INCY
+$3.53M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$2.94M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.18M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$1.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.37M

Top Sells

1
GIS icon
General Mills
GIS
+$2.52M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$2.31M
3
AMGN icon
Amgen
AMGN
+$2.08M
4
ABT icon
Abbott
ABT
+$1.72M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.56M

Sector Composition

1 Healthcare 41.81%
2 Consumer Discretionary 7.1%
3 Consumer Staples 6.25%
4 Communication Services 0.99%
5 Materials 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KO icon
176
CALL
Coca-Cola
KO
$351B
$15K 0.02%
54,200
-75,800
-58% -$3.45M
KR icon
177
CALL
Kroger
KR
$36B
$15K 0.02%
64,200
+39,200
+157% +$883K
LJPC
178
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
$15K 0.02%
+2,700
New +$86.8K
WMT icon
179
PUT
Walmart Inc
WMT
$909B
$14K 0.02%
+15,000
New +$394K
LUMO
180
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$14K 0.02%
+2,222
New +$170K
ARNA
181
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$14K 0.02%
+10,000
New +$229K
TWX
182
PUT
DELISTED
Time Warner Inc
TWX
$14K 0.02%
8,000
+4,000
+100% +$406K
ISRG icon
183
PUT
Intuitive Surgical
ISRG
$122B
$13K 0.02%
13,500
-63,900
-83% -$6.96M
KMB icon
184
CALL
Kimberly-Clark
KMB
$36B
$12K 0.02%
15,700
+700
+5% +$85.5K
GIS icon
185
CALL
General Mills
GIS
$20.3B
$10K 0.02%
108,600
-15,400
-12% -$844K
MNST icon
186
CALL
Monster Beverage
MNST
$95.4B
$10K 0.02%
+20,000
New +$539K
SPY icon
187
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$10K 0.02%
+25,000
New +$6.16M
AZN icon
188
CALL
AstraZeneca
AZN
$262B
$9K 0.01%
23,700
-6,350
-21% -$401K
CLX icon
189
CALL
Clorox
CLX
$11.6B
$9K 0.01%
22,000
-3,200
-13% -$430K
TEVA icon
190
CALL
Teva Pharmaceuticals
TEVA
$37.3B
$9K 0.01%
+20,000
New +$450K
POT
191
CALL
DELISTED
Potash Corp Of Saskatchewan
POT
$9K 0.01%
5,000
-86,300
-95% -$1.54M
DXCM icon
192
PUT
DexCom
DXCM
$29.6B
$8K 0.01%
+40,000
New +$707K
PEP icon
193
CALL
PepsiCo
PEP
$187B
$8K 0.01%
48,900
-7,500
-13% -$866K
RCKT icon
194
CALL
Rocket Pharmaceuticals
RCKT
$376M
$7K 0.01%
3,725
-23,650
-86% -$108K
VZ icon
195
PUT
Verizon
VZ
$182B
$7K 0.01%
22,500
+7,500
+50% +$353K
ALXN
196
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
$7K 0.01%
+5,600
New +$761K
QURE icon
197
PUT
uniQure
QURE
$2.77B
$6K 0.01%
50,000
+46,000
+1,150% +$370K
TDG icon
198
PUT
TransDigm Group
TDG
$67.9B
$5K 0.01%
10,700
– –
AIMT
199
PUT
DELISTED
Aimmune Therapeutics
AIMT
$5K 0.01%
+16,000
New +$345K
CCEP icon
200
Coca-Cola Europacific Partners
CCEP
$46.5B
$4K 0.01%
+100
New +$4.24K
6 7
8
9 10

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2017 Portfolio in Review

As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

FT Options deployed $122M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.

  • FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
  • FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
  • FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
  • FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
  • FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
  • FT Options opened 108 new positions and closed 72 in Q3 2017.
  • FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.